Today Pfizer and BioNTech have jointly announced they are prepared to begin their Phase II/III global trials for their COVID-19 vaccine partnership. Following on review of Phase I/II trial results, the partnership worked with the FDA to select BNT162b2 as the vaccine candidate in the next phases.
Pfizer and BioNTech biopharmaceutics announced today a $1.95 billion dollar agreement with the U.S. government for 100 million doses of the partnership's BNT162 program vaccine.
In a press release from Oracle today, the computing and networking giant announced a partnership with The National Institute of Allergy and Infectious Diseases (NIAID) on a newly established COVID-19 Prevention Network or CoVPN.
Materials science company SiO2 issued a press release announcing a $143 million agreement with the US Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear...
We spoke with Pfizer today and confirmed October remains feasible but is contingent on successful aquisition of an Emergency Use Declaration
Anti-vaccine rhetoric is actually nothing new, but its expanded visibility is beginning to show changes in public behavior. Gradually, more parents are choosing not to vaccinate their children and cases of preventable diseases are already sounding their echo.
The U.S. Department of Defense (DoD) is investing $71 million in Pennsylvania based Inovio Pharmaceuticals in order to expedite the production of the COVID-19 vaccine. In a press release today, Inovio referenced their CELLECTRA® 3PSP...
This week, The Guardian reported on a growing concern the Trump administration may be pressuring government agencies including the FDA to approve a COVID-19 vaccine in time for the US election